Lexaria Bioscience
LEXXLexaria Bioscience Corp. (NASDAQ: LEXX) is a Canadian biotechnology company focused on the development and licensing of its patented DehydraTECH™ drug delivery platform. The company's primary business is improving the bioavailability and speed of onset for orally administered fat-soluble active pharmaceutical ingredients and cannabinoids. DehydraTECH is designed to enhance the delivery of these compounds through the intestinal tract and across the blood-brain barrier. The DehydraTECH platform has been the subject of multiple in vivo and human clinical studies, which have demonstrated its ability to increase the bioavailability of certain drugs. Lexaria operates through a licensing model, partnering with other companies to incorporate DehydraTECH into their product development pipelines. The company's research has spanned several therapeutic areas, including hypertension, diabetes, and antiviral applications, with studies specifically investigating the delivery of drugs like sildenafil and antiviral compounds. Publicly traded on the NASDAQ under the ticker LEXX, Lexaria Bioscience holds a portfolio of granted patents in multiple jurisdictions worldwide for its DehydraTECH technology. The company's work is directed towards creating more efficient oral delivery methods for existing and new pharmaceutical products, with the goal of improving patient dosing regimens and outcomes.
LEXX · Stock Price
Historical price data
About
Lexaria Bioscience Corp. (NASDAQ: LEXX) is a Canadian biotechnology company focused on the development and licensing of its patented DehydraTECH™ drug delivery platform. The company's primary business is improving the bioavailability and speed of onset for orally administered fat-soluble active pharmaceutical ingredients and cannabinoids. DehydraTECH is designed to enhance the delivery of these compounds through the intestinal tract and across the blood-brain barrier. The DehydraTECH platform has been the subject of multiple in vivo and human clinical studies, which have demonstrated its ability to increase the bioavailability of certain drugs. Lexaria operates through a licensing model, partnering with other companies to incorporate DehydraTECH into their product development pipelines. The company's research has spanned several therapeutic areas, including hypertension, diabetes, and antiviral applications, with studies specifically investigating the delivery of drugs like sildenafil and antiviral compounds. Publicly traded on the NASDAQ under the ticker LEXX, Lexaria Bioscience holds a portfolio of granted patents in multiple jurisdictions worldwide for its DehydraTECH technology. The company's work is directed towards creating more efficient oral delivery methods for existing and new pharmaceutical products, with the goal of improving patient dosing regimens and outcomes.